Analysis Clover Health Investments, Corp. (CLOV)
6/3/2024
Analysis of Clover Health Investments, Corp. (CLOV)
Clover Health Investments, Corp. (CLOV) has shown some interesting price movements recently. The stock closed at $1.10 on May 31st, after opening at $1.15. The price ranged from a low of $1.08 to a high of $1.16.Key technical indicators suggest that the stock may be overbought, as the RSI indicator is at 68.81, indicating a potential reversal in the short term. The MACD indicator is positive at 0.08798, with the MACD line above the signal line, suggesting bullish momentum.
In terms of moving averages, the stock is trading above the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA), indicating a positive trend.
Overall, while the technical indicators suggest bullish momentum, the overbought RSI and potential reversal signal caution for a possible correction in the near future. Investors should closely monitor the stock's price action and key support levels for potential entry or exit points.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price summary shows a beta value, moving averages, and the range of the stock price over the past year.
Valuation metrics reveal the company's price-to-earnings ratios, price-to-book ratio, and other key financial indicators. The enterprise value, market capitalization, and other valuation measures provide insights into the company's financial health.
Lastly, dividends and splits information includes details about dividend payments, dividend yields, and historical split events for the company's stock. This data can be useful for investors looking at the company's dividend policy and historical performance.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's revenue has been increasing steadily over the past four fiscal years.
2. The gross profit margin seems to be relatively stable, with fluctuations in cost of goods sold.
3. Earnings before interest and taxes (EBIT) have also shown an increasing trend.
4. Net income has been growing consistently, indicating good profitability.
5. Earnings per share (EPS) have shown a positive trend, reflecting well on the company's financial performance.
6. The company has been able to manage its operating expenses effectively, as seen in the growth of operating income.
7. Non-operating interest expenses have been relatively stable over the years.
8. The number of basic and diluted shares outstanding has remained constant, indicating no significant dilution of shares.
9. Overall, the financial performance of the company, in terms of revenue and profitability, appears to be on a positive trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, peaking at $234,386,000,000 in 2018.
4. Total liabilities have also been on the rise, with the highest value in 2018 at $255,355,000,000.
5. Shareholders' equity has generally increased, with the highest value in 2018 at $107,147,000,000.
6. The company has been investing more in non-current assets and retaining earnings over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, with large amounts being spent on common stock repurchase and debt issuance and payments.
4. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments.
5. The end cash position has been fluctuating, but overall, the company seems to be maintaining a healthy cash balance.
6. Interest paid has been relatively stable over the years, while income tax paid shows some variation.
7. Stock-based compensation has been increasing over the years, indicating a potential focus on employee incentives through stock options.
8. The company has been paying dividends consistently, with varying amounts each year.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% from the previous year's quarter. The number of analysts providing estimates remains at 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, indicating a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates remains at 38.
Overall, the estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with a more substantial increase expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions about the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is slightly higher at 5.2%.
3. Current Year: The growth rate for the current year is estimated to be 7.6%.
4. Next Year: The growth rate for the next year is expected to increase to 9.7%.
5. Past 5 Years: Over the past 5 years, the company has seen an average annual growth rate of 20.15%.
6. Next 5 Years: Looking ahead, analysts project an average annual growth rate of 9.72% for the next 5 years.
These estimates suggest that the company is expected to experience steady growth in the upcoming periods, with a significant increase in growth rate compared to the past year.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the average at $204.58. The current price of the security is $192.25, which falls below the median and average forecasted prices. Investors may consider these forecasts when making decisions about buying or selling the security.
MACD of CLOV
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
